Crohn's Disease
Conditions
Brief summary
This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.
Detailed description
Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore, their immunomodulatory effects are significant for treating immune-related diseases, such as crohn's disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease.
Interventions
BIOLOGICALALLO-ASC
Infusion for Crohn's disease
Sponsors
Anterogen Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is 18 to 65 years of age 2. Subject who is diagnosed Crohn's disease by endoscopic or radiologic result during more than 6 months 3. Subject who show intolerance or failure of conventional therapy (steroids, immunosuppressive and TNF-alpha inhibitor) 4. Subject who is included CDAI 220-450 during screening period 5. CRP\>0.5mg/dL during screening period 6. Subject who show affected sites by crohn's disease in either ileum and large intestine or both of them, including more than 1 nonanastomotic ulcers as a result of colonoscopy. 7. Subjects who satisfy those clinical examination value below during screening period. A. Hemoglobin ≥ 8.0g/dL B. WBC ≥ 3,000/μL C. Lymphocyte ≥ 500/μL D.100,000/μL ≤ Platelet ≤ 1,200,000/μL E. AST and ALT ≤ 3 x the upper limit of normal F. ALP ≤ 3 x the upper limit of normal G.Serum creatinine ≤ the upper limit of normal H.Serum albumin ≥ 2.0g/dL I.PT , aPTT≤ the upper limit of normal 8. Negative for urine beta-HCG for women of childbearing age. 9. Subject is able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion criteria
1. Subject with gastro-intestinal tract A. Crohn's disease which is invaded only proximal ileum. B. The evidence of an intra abdominal abscess during screening period. C. The evidence of an abscess around the anus during screening period. D. Conditions of subtotal colectomy or total colectomy. E. Short bowel syndrome. F. Subject who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before enrollment. G. Subject who have ileostomy or colostomy. H Subject who have a bowel stricture of large intestine that may be significant by PI's decision during screening period. I. In case that the PI anticipates that patients need to get a surgical intestinal tract surgery caused by crohn's disease. J. Subject who have adenoma of large intestine K. Subject who have chronic inflammation-associated dysplasia. 2. Subjects who have been received biological therapy within 60 days of enrollment.. 3. Subject with infectious disease A. Acute or chronic active HBV, HAV and HIV B. Active tuberculosis. C. IGRA (Interferon-Gamma Release Assay) positive D. All kinds of live vaccine inoculation except influenza vaccine within 4weeks before registration E. Pneumonia, pyelonephritis and Infection of Clostridium within 4weeks during screening visit. F.Subject has history of bacteremia or other serious bacterial or fungal infection in past 3 months. 4. Subject who has malignant tumor or which is not cured yet 5. Subject has any serious disease, in the opinion of the Investigator, would interfere with the evaluation of the study. 6. Subject who has history of blood clots and other pathological arterial thrombosis or venous thrombosis 7. Subject who has a hypersensitive reaction to bovine-derived proteins 8. Subject who is surgery or trauma within 6 weeks before registration 9. Subject who is pregnant or breast-feeding. 10. Subjects who are unwilling to use an effective method of contraception during the study 11. Subject who is experienced stem cell therapy 12. Subject who has been enrolled in another clinical study within 4weeks days of screening 13. Subject who has history of alcohol or drug abuse. 14. Subject who is not able to understand the objective of this study or to comply with the study requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety (Clinically measured abnormality of laboratory tests and adverse events) | up to 4 weeks | Clinically measured abnormality of laboratory tests and adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CDAI value | up to 4 weeks | Change in the CDAI value |
| The ratio of patients applicable to CDAI <150 | Week 4 | The ratio of patients applicable to CDAI \<150 |
Countries
South Korea
Contacts
Primary ContactWon Ho Kim, MD., PhD
Outcome results
None listed